Additional information
Funding
This work was supported by the Swiss National Science foundation, the Gottfried and Julia Bangerter-Rhyner-Foundation, and the Freiwillige Akademische Gesellschaft Basel
Related publications
Main article
Stefan Schandelmaier, Matthias Briel, Ravi Varadhan, Christopher Schmid, Phd, Niveditha Devasenapathy, Rodney Hayward, Md, Joel j Gagnier, Michael Borenstein, Geert JMG VanDerHeijden, Issa J Dahabreh, Xin Sun, Willi Sauerbrei, Michael Walsh, John Ioannidis, Lehana Thabane, Gordon Guyatt. 2020. “A New Instrument to Assess the Credibility of Effect Modification Analyses (ICEMAN) in Randomized Controlled Trials and Meta-Analyses.” CMAJ. 2020 192(32):E901-E906
The PATH statement that endorses ICEMAN
Kent DM, Paulus JK, van Klaveren D, D'Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HP, Varadhan R, Vickers A, Wong JB, Steyerberg EW. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. Ann Intern Med. 2020 Jan 7;172(1):35-45.
A related systematic survey of previous credibility criteria
Schandelmaier S, Chang Y, Malgorzata B, Devasenapathy N, Devji T, Kwong JSW, Colunga Lozano LE, Lee Y, Agarwal A, Bhatnagar N, Ewald H, Zhang Y, Sun X, Thabane L, Walsh M, Briel M, Guyatt GH. A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analyses. J Clin Epidemiol. 2019 Sep;113:159-167.
Research on research using ICEMAN (ongoing)
Schandelmaier S, Schmitt AM, Herbrand AK, Glinz D, Ewald H, Briel M, Guyatt GH, Hemkens LG, Kasenda B. Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey. BMJ Open. 2020 May 30;10(5):e034565.
Related doctoral thesis
Schandelmaier, Stefan. 2019. “Evaluating the Credibility of Effect Modification Claims in Randomized Controlled Trials and Meta-Analyses.” PhD. Doctoral Thesis Published on Macsphere.